- Q2-2018 ·
Frost & Sullivan Independent Equity Research
Cellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged.
Report type: Q2-2018 Update Report
Published on: 20 August, 2018
Cellect research articles:
All articles loaded
No more articles to load